Propentofylline for dementia
Sübutlu məlumatların xülasələri
15.07.2017 • Sonuncu dəyişiklik 15.07.2017
Editors
Propentofylline may benefit cognition, global function and activities of daily living of people with Alzheimer's disease and/or vascular dementia.
A Cochrane review included 9 studies with a total of 2 443 subjects. There were detailed reports of only four of the nine included studies. The following statistically significant treatment effects in favour of propentofylline are reported:
- Cognition at 3, 6 and 12 months including MMSE at 12 months (MD 1.2, 95%CI 0.12 to 2.28)
- Severity of dementia at 3, 6 and 12 months including CGI at 12 months (MD -0.21, 95%CI -0.39 to -0.03)
- Activities of Daily Living (NAB) at 6 and 12 months (MD -1.20, 95%CI -2.22 to -0.18)
- Global Assessment (CGI) at 3 months (MD -0.48, 95% CI -0.75 to -0.21), but not at later times.
- Tolerability: There were minimal data on adverse effects and drop-outs. There were a statistically significant treatment effects in favour of placebo at 12 months, for the number of dropouts (OR=1.43, 95%CI 1.04 to 1.90).
Comment: The quality of evidence is downgraded by limitations in study quality (poor reporting) and by potential reporting bias (only positive trials reported). Propentofylline remains an unlicensed drug under commercial development.
Ədəbiyyat
- Frampton MA, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev. 2003;(2):CD002853 (Last assessed as up-to-date: 15 April 2008).